Vycor Medical GAAP EPS of $0.00, revenue of $0.41M
Vycor Medical reported Q3 GAAP EPS of $0.00 and revenue of $0.41M, down 19.6% year-over-year, according to the company's press release.
VYCOR MEDICAL INC
Vycor Medical develops and markets neurosurgical medical devices and provides non-invasive rehabilitation therapies for people with vision disorders caused by neurological brain damage, including stroke. Its two business units are Vycor Medical and NovaVision. Vycor Medical’s product, the ViewSite Brain Access System (VBAS), is a retraction and access system for brain and spine surgeries. NovaVision offers computer-based rehabilitation therapies for people with impaired vision following stroke or other brain injury. Vycor Medical makes and markets medical devices, while NovaVision provides rehabilitation therapies. The company operates across the medical device industry and uses shared resources across its divisions. Vycor Medical is headquartered in Boca Raton, Florida.
No SEC Form 4 filings for $VYCO in the last 30 days.
See all $VYCO insider activity →Vycor Medical reported Q3 GAAP EPS of $0.00 and revenue of $0.41M, down 19.6% year-over-year, according to the company's press release.
VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026 BOCA RATON, FL (November 13, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and nine months ended September 30, 2026.
Vycor Medical, Inc. (VYCO) reported a 19% year-over-year decline in Q3 2026 revenue to $414.9K, with nine-month revenue down 11% to $1.3M. GAAP net losses were $161.4K for Q3 and $325.8K for the nine-month period, though prior-period net loss figures were not provided.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning VYCO (VYCOR MEDICAL INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 6 bearish.
Earnings miss with zero EPS and declining revenue likely pressures the stock.
Revenue fell 19% YoY and operating profit dropped, indicating weakening demand.
Revenue decline and widening losses suggest continued pressure on the stock.
The release shows weakening top-line trends, especially in international VBAS sales, alongside improved GAAP operating profit vs 2025 for the six-month period.
The 8-K discloses a clear earnings deterioration versus 2025, driven largely by international revenue weakness and lower operating profit.
AlphAI scores every news story that mentions VYCO with an AI model for sentiment and relevance, and aggregates insider trades from VYCOR MEDICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Vycor Medical reported Q3 GAAP EPS of $0.00 and revenue of $0.41M, down 19.6% year-over-year, according to the company's press release.
VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Nine Months Ended September 30, 2026 BOCA RATON, FL (November 13, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and nine months ended September 30, 2026.
Vycor Medical, Inc. (VYCO) reported a 19% year-over-year decline in Q3 2026 revenue to $414.9K, with nine-month revenue down 11% to $1.3M. GAAP net losses were $161.4K for Q3 and $325.8K for the nine-month period, though prior-period net loss figures were not provided.
Vycor Medical, Inc. (OTCQB: VYCO) reported revenue of $418.3k for the three months ended June 30, 2026, down 16% from 2025, and $876.8k for six months, down 6%. Vycor Medical (VBAS) revenue fell 17% (quarter) and 7% (six months). GAAP operating profit was $6.9k (quarter) and $52.7k (six months).
VYCOR MEDICAL INC (VYCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026 BOCA RATON, FL (August 14, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three and six months ended June 30, 2026. The Company op